Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aadi Bioscience (AADI)
NASDAQ:AADI
Holding AADI?
Track your performance easily
AADI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.21 - $7.24
Previous Close$1.58
Volume696.79K
Average Volume (3M)280.29K
Market Cap
$38.89M
Enterprise Value-$38.62M
Total Cash (Recent Filing)$78.57M
Total Debt (Recent Filing)$1.06M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Nov 06, 2024EPS Estimate
-$0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.43
Shares Outstanding24,614,834
10 Day Avg. Volume618,228
30 Day Avg. Volume280,287
Standard Deviation0.21
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.48
Price to Sales (P/S)1.60
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.62
Enterprise Value/Gross Profit-1.79
Enterprise Value/Ebitda0.59
Forecast
1Y Price Target
$1.50Price Target Upside-5.06% Downside
Rating ConsensusHold
Number of Analyst Covering3
Aadi Bioscience News
PremiumCompany Announcements
Aadi Bioscience Executives Transition with Continued Roles
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCompany continues label-expanding effort with two ongoing Ph2 studies in EEC and NETs, which has enrolled sufficient patients to access initial efficacy.
Operational StrategyCompany will reduce 80% R&D workforce and extend cash runway into at least the second half of 2026.
Sales PerformanceFyarro remains the only preferred treatment for PEComa and has achieved $51.1M sales since 2022 launch.
Bears Say
Clinical TrialsAadi announced it will halt the registration-intended PRECISION1 Phase 2 trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations.
Financial StrategyThe company will preserve cash runway by pausing enrollment in the ongoing Phase I NET and EEC trials and reducing its R&D workforce by 80%.
Market PenetrationThere remains little upside for Aadi with nab-sirolimus because the company may have already penetrated the bulk of the target market in PEComa—the only indication currently on the FYARRO label.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
AADI FAQ
What was Aadi Bioscience’s price range in the past 12 months?
Aadi Bioscience lowest stock price was $1.21 and its highest was $7.24 in the past 12 months.
What is Aadi Bioscience’s market cap?
Currently, no data Available
When is Aadi Bioscience’s upcoming earnings report date?
Aadi Bioscience’s upcoming earnings report date is Nov 06, 2024 which is in 74 days.
How were Aadi Bioscience’s earnings last quarter?
Aadi Bioscience released its earnings results on Aug 07, 2024. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.69 by $0.15.
Is Aadi Bioscience overvalued?
According to Wall Street analysts Aadi Bioscience’s price is currently Overvalued.
Does Aadi Bioscience pay dividends?
Aadi Bioscience does not currently pay dividends.
What is Aadi Bioscience’s EPS estimate?
Aadi Bioscience’s EPS estimate is -$0.47.
How many shares outstanding does Aadi Bioscience have?
Aadi Bioscience has 24,614,834 shares outstanding.
What happened to Aadi Bioscience’s price movement after its last earnings report?
Aadi Bioscience reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.69. Following the earnings report the stock price went down -3.571%.
Which hedge fund is a major shareholder of Aadi Bioscience?
Currently, no hedge funds are holding shares in AADI
---
Aadi Bioscience Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.50 (-5.06% Downside)
$1.50 (-5.06% Downside)
Blogger Sentiment
Neutral
AADI Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.08%
12-Months-Change
Fundamentals
Return on Equity
-62.26%
Trailing 12-Months
Asset Growth
-32.80%
Trailing 12-Months
Company Description
Aadi Bioscience
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. Its product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 17, 2011 and is headquartered in Cincinnati, OH.
---
AADI Earnings Call
Q2 2024
0:00 / 0:00
---
AADI Stock 12 Month Forecast
Average Price Target
$1.50
▼(-5.06% Downside)
Technical Analysis
Best Analysts Covering AADI
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-51.11%
assigned a buy rating 8 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -51.11% per trade.
---